Sanjiv S. Agarwala - Researcher Profile

Publications

3 shown

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow , Jason Chesney , Anna C. Pavlick +18 more

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...

2015 New England Journal of Medicine 2716 citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

Paul B. Chapman , Lawrence H. Einhorn , Michael L. Meyers +9 more

PURPOSE: Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor responses...

1999 Journal of Clinical Oncology 756 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 5,000
Institution: St. Luke's University Health Network

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-9416-8768

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.